In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...
Fintel reports that on February 11, 2025, Oppenheimer initiated coverage of International Business Machines (NYSE:IBM) with a ...
Oppenheimer reiterated its Outperform rating and $115.00 price target for Gilead Sciences (NASDAQ:GILD) stock, following a strong fourth-quarter performance that surpassed consensus estimates. Gilead ...
Investing.com -- Oppenheimer analysts warned that Tesla (NASDAQ: TSLA) faces rising risks as competition in both electric and ...
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “market perform” rating restated by analysts at Oppenheimer in a research note issued to investors on Monday, MarketBeat.com reports ...
In a report released today, Jeff Jones from Oppenheimer reiterated a Buy rating on Alumis Inc. (ALMS – Research Report), with a price target of ...
Cillian Murphy’s dedication to Oppenheimer went beyond acting—he learned 30,000 words of Dutch, followed a brutal diet, and ...
Benny Safdie is the latest actor to join the cast of The Odyssey, the next movie from Christopher Nolan, according to The ...
Oppenheimer downgraded Apple from "outperform" to "perform" because it is struggling to adapt to a competitive AI landscape.
Director Christopher Nolan is set to reunite with one of the stars from his multi-award-winning film Oppenheimer for his next ...
Within financials ( XLF ), Wald mentioned capital markets and the SPDR S&P Capital Markets ETF ( KCE) as a top idea, representing high momentum. Among top stocks, he mentioned Carlyle Group ( CG ), ...